Vaxxas

Vaxxas is advancing the Nanopatch as a needle-free vaccine delivery device to radically improve the global reach of effective vaccines. The Nanopatch is designed to optimally target immunologically sensitive cells within the skin's outer layers -a new and better way of vaccinating against infectious disease. Founded in 2011, Vaxxas has 24 employees and investments from a venture capital consortium and from Merck and the World Health Organization. Vaxxas R&D is underpinned by the research undertaken within the University of Queensland.